Screening of Psychoactive Substances Use and Anxio-depressive Disorders in Consultation for HIV Pre-exposure Prophylaxis
| Registry | NCT03449771, acronym PrEP |
|---|---|
| Status | Terminated - Inclusion of the last patient |
| Phase | Not applicable |
| Study type | Interventional; na, single group, masking: none, other |
| Enrollment | 237 (Actual) |
| Sponsor | University Hospital, Montpellier (Other) |
| Conditions | Psychoactive Substance Use, Mood Disorders |
| Interventions | self-administered questionnaire (Other) |
| Dates | start 2018-01-03, primary completion 2019-07-03, completion 2019-11-03, first posted 2018-02-28, last updated 2021-12-30 |
| Locations | 5 sites in France |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Psychoactive Substance Use All trials for Mood Disorders All trials of self-administered questionnaire
HIV pre-exposure prophylaxis (PrEP) with Truvada®, a combination of two antiretrovirals (tenofovir \& emtricitabine) is a prevention strategy for HIV-negative people at high risk of acquiring HIV. PrEP has thus been integrated as a new tool to significantly reduce the risk of HIV infection, especially among men who have sex with men (MSM). Since its introduction, an increase in sexually transmitted infections (STIs) has been observed, particularly in relation to the use of psychoactive substances in a sexual context (Chemsex).
In this context, the description and evaluation of these practices seem necessary, as well as the impact on the risk of addiction and mental health.
Interventional, multi-center pilot study, including all subjects aged 18 years or older presenting in consultation for a PrEP renewal.
The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale). After consent, the answers will be discussed with the doctor during the consultation for appropriate care, including a referral to a psychiatrist and / or addictologist if necessary.
The duration of the inclusions will be 6 months and the number of patients to include is 250.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Single Arm | Experimental | Other: self-administered questionnaire | To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Subject aged over 18, * Subject seen in consultation in one of the centers of the study for a renewal of the Prep * Subject having agreed to participate in the study Exclusion Criteria: * Subject not speaking French / illiterate
| Facility | City | Country | Status |
|---|---|---|---|
| Hospital of Alès | Alès | France | |
| Uh Montpellier | Montpellier | France | |
| CEGIDD | Nîmes | France | |
| UH NIMES | Nîmes | France | |
| Hospital of Perpignan | Perpignan | France |